Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton(National Cancer Centre Japan), Susie Jun(Ellis Hospital), Gary Richardson(Cabrini Hospital), Boris Bilynskyy, Denise A. Yardley(Sarah Cannon), Philippe Beuzeboc(Hôpital Foch), Salvatore Siena(University of Milan), Veena Charu, Pablo Maroto(Hospital de Sant Pau), Karim Fizazi(Université de Lille), Janet E. Brown(University of Sheffield), Chunlei Ke(Amgen (United States)), María Eugenia Ibarrarán Viniegra(National Cancer Centre Japan), David H. Henry(Pennsylvania Hospital), Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), Ada Braun(National Cancer Centre Japan), Michael Rader(Nyack Hospital), Fred Saad(Centre Hospitalier de l’Université de Montréal), Alison Stopeck(National Cancer Centre Japan)
Cited by 588
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k